You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • AB0423 Impact of Anti-IL-6 Monoclonal Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase Iib Study

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Abstracts accepted for publication. Rheumatoid arthritis - other biologic treatment
AB0423 Impact of Anti-IL-6 Monoclonal Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase Iib Study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alemao E, Joo S, Banerjee S, et al
AB0423 Impact of Anti-IL-6 Monoclonal Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase Iib Study
Annals of the Rheumatic Diseases 2014;73:947.